Nelkarmi Approved in US for Previously Treated Advanced ALK-Positive Lung Cancer
The approval was based on the phase I/II ALKOVE-1 trial, which demonstrated clinically meaningful and durable response.
The approval was based on the phase I/II ALKOVE-1 trial, which demonstrated clinically meaningful and durable response.